Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simona Colla

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
Biorxiv : the Preprint Server for Biology|March 3, 2023
Targeting DNA2 Overcomes Metabolic Reprogramming in Multiple MyelomaNatthakan Thongon, Feiyang Ma, Pamela Lockyer, et al.
Cancer Discovery|October 11, 2011
PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine networkHaoqiang Ying, Kutlu G Elpek, Anant Vinjamoori, et al.
Nature|August 15, 2014
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial functionAndrea Viale, Piergiorgio Pettazzoni, Costas A Lyssiotis, et al.
Blood Cancer Discovery|August 4, 2022
Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed SideroblastsVera Adema, Feiyang Ma, Rashmi Kanagal-Shamanna, et al.
Nature|April 8, 2026
Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial functionAndrea Viale, Piergiorgio Pettazzoni, Costas A Lyssiotis, et al.
Leukemia|February 17, 2026
A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemiaSamarpana Chakraborty, Claudia Morganti, Kimberly Zaldana, et al.
Nature|February 11, 2011
Telomere dysfunction induces metabolic and mitochondrial compromiseErgün Sahin, Simona Colla, Marc Liesa, et al.
Nature Communications|June 4, 2024
Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AMLMatteo Marchesini, Andrea Gherli, Elisa Simoncini, et al.
Biorxiv : the Preprint Server for Biology|March 23, 2026
Aberrant oxidative metabolism selects for <i>TET2</i> -deficient hematopoietic stem and progenitor cellsKatia E Niño, Vera Adema, Alyx E Gray, et al.
Nature Medicine|March 4, 2022
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapyIrene Ganan-Gomez, Hui Yang, Feiyang Ma, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Biorxiv : the Preprint Server for Biology|March 3, 2023
Targeting DNA2 Overcomes Metabolic Reprogramming in Multiple MyelomaNatthakan Thongon, Feiyang Ma, Pamela Lockyer, et al.
Cancer Discovery|October 11, 2011
PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine networkHaoqiang Ying, Kutlu G Elpek, Anant Vinjamoori, et al.
Nature|August 15, 2014
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial functionAndrea Viale, Piergiorgio Pettazzoni, Costas A Lyssiotis, et al.
Blood Cancer Discovery|August 4, 2022
Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed SideroblastsVera Adema, Feiyang Ma, Rashmi Kanagal-Shamanna, et al.
Nature|April 8, 2026
Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial functionAndrea Viale, Piergiorgio Pettazzoni, Costas A Lyssiotis, et al.
Leukemia|February 17, 2026
A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemiaSamarpana Chakraborty, Claudia Morganti, Kimberly Zaldana, et al.
Nature|February 11, 2011
Telomere dysfunction induces metabolic and mitochondrial compromiseErgün Sahin, Simona Colla, Marc Liesa, et al.
Nature Communications|June 4, 2024
Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AMLMatteo Marchesini, Andrea Gherli, Elisa Simoncini, et al.
Biorxiv : the Preprint Server for Biology|March 23, 2026
Aberrant oxidative metabolism selects for <i>TET2</i> -deficient hematopoietic stem and progenitor cellsKatia E Niño, Vera Adema, Alyx E Gray, et al.
Nature Medicine|March 4, 2022
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapyIrene Ganan-Gomez, Hui Yang, Feiyang Ma, et al.
Pageof 10